New treatment options have changed the survival of patients with follicular lymphoma.

Publication Type:

Journal Article


Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 23, Issue 33, p.8447-52 (2005)


Adolescent, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Cyclophosphamide, Disease-Free Survival, Doxorubicin, Etoposide, Female, Humans, Leucovorin, Lymphoma, Follicular, Male, Mechlorethamine, methotrexate, Middle Aged, Multivariate Analysis, Prednisone, Procarbazine, Proportional Hazards Models, Prospective Studies, Survival Rate, United States, Vincristine


The natural history of follicular lymphoma is believed not to have changed over the last 30 years. Median survivals have ranged from 7 to 10 years, and the disease is considered incurable. However, multiple new treatment options have been developed in the last decade, and their impact on survival of follicular lymphoma remains unknown.